Evidence map›Paper›PMID 39522011›Full record

ArticleBMC cancer2024

Establishment of potential lncRNA-related hub genes involved competitive endogenous RNA in lung adenocarcinoma.

Yong Li, Danfei Shi, Yan Jiang, Yanqin Hu, Qiuxia Liu, Yanping Xie, Xilin Zhang

Abstract read
In one paragraph

Article in BMC cancer, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Yong LiDepartment of Laboratory Medicine, First Affiliated Hospital of Huzhou University, Huzhou, 313000, Zhejiang, China.
Danfei ShiDepartment of Pathology, First Affiliated Hospital of Huzhou University, Huzhou, 313000, Zhejiang, China.
Yan JiangDepartment of Respiratory Medicine, First Affiliated Hospital of Huzhou University, No. 158 Guangchang Back Road, Huzhou, Zhejiang, 313000, P. R. China.
Yanqin HuDepartment of Laboratory Medicine, First Affiliated Hospital of Huzhou University, Huzhou, 313000, Zhejiang, China.
Qiuxia LiuDepartment of Laboratory Medicine, First Affiliated Hospital of Huzhou University, Huzhou, 313000, Zhejiang, China.
Yanping XieDepartment of Respiratory Medicine, First Affiliated Hospital of Huzhou University, No. 158 Guangchang Back Road, Huzhou, Zhejiang, 313000, P. R. China.
Xilin ZhangCentral Laboratory, Huzhou Key Laboratory of Translational Medicine, First Affiliated Hospital of Huzhou University, No. 158 Guangchang Back Road, Huzhou, Zhejiang, 313000, P. R. China. zhangxilin16@126.com.

Funding

Huzhou Science and Technology Fund under Grant no 2021GZB03The Scientific Technology Projects of Health and Medicine of Zhejiang Province under Grant nos 2023KY1180The Scientific Technology Projects of Health and Medicine of Zhejiang Province under Grant nos 2023KY318Zhejiang Provincial Natural Science Foundation of China under Grant Nos LTGY23H160004Zhejiang Provincial Natural Science Foundation of China under Grant Nos LY22H160026
6 · The paper itself

Abstract

Long non-coding RNAs (lncRNAs) have a notable role in the diagnosis and prognosis of cancer. However, the associations between lncRNA-related hub genes (LRHGs) expression and the corresponding outcomes have not been fully understood in lung adenocarcinoma (LUAD). Here, a total of 71 patients diagnosed with LUAD and 60 healthy volunteers at The First Affiliated Hospital of Huzhou University from April, 2023 to December, 2023 were enrolled in the present study. A LRHGs model was established using least absolute shrinkage and selection operator analyses of The Cancer Genome Atlas-LUAD datasets. The underlying mechanisms of the LRHGs were investigated via Gene Set Enrichment Analysis and Gene Set Variation Analysis. Additionally, the diagnostic role of serum HOXD cluster antisense RNA 2 (HOXD-AS2) was assessed by receiver operating characteristic (ROC) curve analysis. Lastly, TCGA-LUAD samples were divided into high- and low-HOXD-AS2 expression groups based on the median expression. The associations between HOXD-AS2 expression and miR-4538 as well as Calmodulin-Dependent Protein Kinase Type II subunit Beta (CAMK2B) levels were conducted through Pearson correlation analysis. A comprehensive analysis identified 141 differentially expressed lncRNAs between 539 LUAD tissues and 59 normal samples. A prognostic marker for overall survival was established by constructing a predictive signature consisting of 9 LRHGs. Subsequently, 474 LUAD samples were categorized into a high or low-risk group based on the median of the risk score. An independent prognostic model was constructed to confirm the validity of this categorization. Further comparisons of the clinicopathological features and LRHG-related pathways were performed between the two groups. Examinations of LRHG expression in two LUAD clusters and of the association between LRHG expression and immune infiltration were also conducted. HOXD-AS2 expression was shown to be elevated in LUAD tissues compared with matched normal tissues, and the serum HOXD-AS2 level was also notably increased in LUAD samples compared with healthy controls. The results of the ROC analysis indicated that the sensitivity and specificity of HOXD-AS2 were higher than that of cytokeratin-19 fragment (CYFRA21-1), which is a serum marker for LUAD. Pearson analyses indicated that miR-4538 level was negatively associated with HOXD-AS2 expression, but CAMK2B level showed positive correlation in LUAD. The results of the present study therefore indicated that the constructed LRHG model, particularly HOXD-AS2, could independently diagnose and predict the prognosis of LUAD, which suggested the underlying mechanism of the HOXD-AS2/miR-4538/CAMK2B, and might offer efficient strategies for LUAD treatment.

Indexed as

Adenocarcinoma of LungBiomarkers, TumorGene Expression Regulation, NeoplasticLung NeoplasmsRNA, Long NoncodingAgedCalcium-Calmodulin-Dependent Protein Kinase Type 2FemaleGene Expression ProfilingHumansMaleMicroRNAsMiddle AgedPrognosisRNA, Competitive EndogenousROC CurveBiomarkers, TumorCalcium-Calmodulin-Dependent Protein Kinase Type 2MicroRNAsRNA, Competitive EndogenousRNA, Long NoncodingceRNADiagnosisLncRNALung adenocarcinoma

Identifiers

PMID39522011
PMCPMC11549862

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.